Androgen deprivation therapy
Apalutamide has significantly improved overall survival in patients with metastatic hormone-sensitive prostate cancer
The results from the final analysis of the phase 3 TITAN study, which has demonstrated the continued statistically significant benefit...
Non-metastatic castration-resistant prostate cancer - ESMO Clinical Practice Guidelines
Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...
Apalutamide vs placebo in patients with non-metastatic castration-resistant prostate cancer receiving androgen deprivation therapy: health-related quality of life at final analysis of the SPARTAN study
The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...
European Union: Lynparza approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...
Orgovyx, the first oral hormone therapy for treating advanced prostate cancer
The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in...
FDA has approved Orgovyx for advanced prostate cancer
The Food and Drug Administration ( FDA ) has approved the first oral gonadotropin-releasing hormone ( GnRH ) receptor antagonist,...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer: final survival results from SPARTAN, a phase III trial
SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...
Darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer: overall survival results of phase III ARAMIS study
Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...
IPATential150 study: Ipatasertib in combination with Abiraterone and Prednisone / Prednisolone met its co-primary endpoint of radiographic progression free survival in patients with PTEN loss tumours
Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...
Erleada for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease, European Commission approved
The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...
Apalutamide improves overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer
Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...
Prostate cancer: hormone therapy may raise risk of Alzheimer's, dementia
For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...
Olaparib in combination with Abiraterone delays disease progression in metastatic castration-resistant prostate cancer
Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...
Safety data from a phase II trial of Radium-223 dichloride plus Enzalutamide versus Enzalutamide alone in men with metastatic castration refractory prostate cancer
Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic...
Enzalutamide prolongs urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer
The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95%...
PROSPER trial: Enzalutamide reduces the risk of metastasis or death by 71% in men with non-metastatic castration-resistant prostate cancer
The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...
SPARTAN trial, Apalutamide, an androgen receptor inhibitor, improves median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer
New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...
Prostate cancer: link between androgen deprivation therapy and dementia
A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...
Abiraterone acetate provides significant clinical benefit in patients with high-risk metastatic hormone-naïve prostate cancer, improving overall survival and radiographic progression-free survival
Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...